Johnson & Johnson Highlights Its Preeminent Leadership in Hematology Through Differentiated Blood Cancer Portfolio and Pipeline With New Clinical and Real-World Data at ASH
December 01, 2023
December 01, 2023
RARITAN, New Jersey, Dec. 1 -- The Janssen Pharmaceutical Companies of Johnson and Johnson issued the following news release on Nov. 29, 2023:
Johnson & Johnson announced today that more than 85 presentations from the Company's robust hematology portfolio and pipeline will be presented at the 65th Annual American Society of Hematology (ASH) Annual Meeting in San Diego from December 9-12. Clinical and real-world data will highlight the Company's differentiated portfolio and pipel . . .
Johnson & Johnson announced today that more than 85 presentations from the Company's robust hematology portfolio and pipeline will be presented at the 65th Annual American Society of Hematology (ASH) Annual Meeting in San Diego from December 9-12. Clinical and real-world data will highlight the Company's differentiated portfolio and pipel . . .